Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
NCT02831751Phase 2Completed
- Sponsor
- Medicago Inc.
- Start
- Apr 2016
- Primary completion
- Jul 2016
- Modality
- Recombinant Protein Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of Quadrivalent VLP Vaccine in influenza (4 arms), sponsored by Medicago Inc. Primary endpoint: Geometric Mean Titers of Hemagglutination Inhibition Antibody against Homologous Influenza Strains at 21 days. Started Apr 2016; status: completed.
02
Drugs
Quadrivalent VLP Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02831751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831751.